KDM1A and neoplasm: LSD1 inhibition increases the expression of key immune checkpoint regulators such as CCL5, CXCL9, and CXCL10 and effector T cell chemokines, which in turn increases CD8+ T cell tumor infiltration and improves the efficacy of immunotherapy [64].